Bristol Myers Squibb Co (BMY) company profile
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
About Bristol Myers Squibb
Pharmaceutical Preparations, SIC 2834
Bristol-Myers Squibb Company engages in the discovery, development, licensing, and commercialization of biopharmaceutical products. Its commercial portfolio and drug development pipeline encompass therapies across multiple therapeutic areas, including immunology, oncology, cardiovascular, hematology, and neuroscience. The company organizes its product offerings into growth brands—such as Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, and Cobenfy—alongside legacy brands including Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane. It generates revenue via direct net product sales, collaborative agreements, and royalties. Key customers and major wholesale distributors include McKesson Corporation, Cencora, and Cardinal Health.
The business operates internationally with commercial sales and collaborative presence across North America, Europe, and Asia. Specific geographic markets and foreign tax jurisdictions explicitly identified in the text include the United States, Switzerland, and Ireland, alongside commercial arrangements covering Japan, South Korea, and Taiwan. The provided text details regional rights and partnerships, but does not state the company's specific headquarters location, store count, founding year, or website domain.
Summary of the business section of Bristol Myers Squibb's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bristol Myers Squibb Co
- Founded
- 1989
- Headquarters
- Princeton, NJ
- Address
- Route 206 And Province Line Road 08543
- Phone
- (609) 252-4621
- Website
- www.bms.com
- Employees
- 32,500, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- DELOITTE & TOUCHE LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- BMY
- Other tickers
- CELG.RI
- Exchange
- NYSE
- Shares outstanding
- 2.04B, Oct 21, 2026
- Public float
- $94.19B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Mar 1, 1999; 2-for-1, Mar 3, 1997; 2-for-1, Jun 10, 1987; 2-for-1, May 27, 1983; 2-for-1, May 31, 1977
- SEC CIK
- 14272
- CUSIP
- 110122108
- ISIN
- US1101221083
- FIGI
- BBG000DQLV23
- Share class FIGI
- BBG001S8N8J6
- LEI
- HLYYNH7UQUORYSJQCN42
- EIN
- 22-0790350
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher S. Boerner | Chief Executive Officer, Director | 148,536 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 32,437 |
| Karin Shanahan | EVP, Chief Supply Chain & Ops | 30,414 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 33,977 |
| Cari Gallman | EVP, General Counsel | 15,876 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 18,748 |
| Bartie Wendy Short | EVP, Corporate Affairs | 12,684 |
| Phil M. Holzer | SVP and Controller | 16,862 |
| David V. Elkins | EVP, Chief Financial Officer | 159,542 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | – |
| Lynelle Hoch | President, Cell Therapy Org. | 5,913 |
| Robert M. Plenge | EVP, Chief Research Officer | 34,826 |
| Ahn Amanda Poole | EVP, Chief People Officer | 6,118 |
| Benjamin Hickey | President, RayzeBio Org. | 16,672 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 83,513 |
| Sandra Leung | EVP, General Counsel | 455,478 |
| Julia A. Haller | Director | 30,279 |
| Michael R. McMullen | Director | 1,000 |
| Phyllis R. Yale | Director | – |
| Peter J. Arduini | Director | – |
| Derica W. Rice | Director | 1,200 |
| Theodore R. Samuels II | Director | 35,500 |
| Deepak Bhatt | Director | – |
| Karen H. Vousden | Director | – |
| Paula A. Price | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $21.88M | $16.86M | $9.22M | $105 | $198 |
| FY2024 | $18.79M | $21.20M | $7.72M | $105 | $154 |
| FY2023 Dr Chris Boerner | $8.46M | $382.57K | $5.92M | $91 | $142 |
| FY2023 Dr Giovanni Caforio | $19.66M | -$6.91M | $5.92M | $91 | $142 |
| FY2022 Dr Chris Boerner | $0 | $0 | $7.00M | $123 | $139 |
| FY2022 Dr Giovanni Caforio | $20.05M | $35.06M | $7.00M | $123 | $139 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Christopher S. Boerner Board Chair and Chief Executive Officer | $1.59M | $0 | $16.06M | $3.75M | $477.49K | $21.88M | +16% |
| David V. Elkins EVP and Chief Financial Officer | $1.14M | $0 | $5.98M | $1.80M | $256.15K | $9.18M | +5% |
| Cristian Massacesi EVP, Chief Medical Officer, Head of Development | $388.46K | $1.13M | $7.85M | $660.88K | $44.62K | $10.07M | – |
| Adam Lenkowsky EVP, Chief Commercialization Officer | $1.13M | $0 | $6.14M | $1.79M | $277.09K | $9.34M | – |
| Greg Meyers EVP, Chief Digital and Technology Officer | $1.07M | $0 | $4.21M | $1.67M | $230.28K | $7.18M | – |
| Samit Hirawat Former EVP, Chief Medical Officer, Head of Development | $964.90K | $0 | $5.82M | $928.66K | $2.63M | $10.33M | +20% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“Demographics : As of December 31, 2025, we had approximately 32,500 employees in 43 countries.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?